Trv Gp Vi LLC Acquires New Shares in Seaport Therapeutics, Inc. $SPTX

Trv Gp Vi LLC bought a new stake in shares of Seaport Therapeutics, Inc. (NASDAQ:SPTX) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 2,061,222 shares of the company’s stock, valued at approximately $44,769,742. Seaport Therapeutics accounts for approximately 0.0% of Trv Gp Vi LLC’s investment portfolio, making the stock its 2nd largest holding. Trv Gp Vi LLC owned 3.85% of Seaport Therapeutics as of its most recent filing with the SEC.

Analyst Ratings Changes

A number of brokerages have weighed in on SPTX. BNP Paribas Exane lowered shares of Seaport Therapeutics to a “market perform” rating in a research report on Tuesday, May 26th. JPMorgan Chase & Co. began coverage on Seaport Therapeutics in a research note on Tuesday, May 26th. They set an “overweight” rating and a $42.00 target price on the stock. HC Wainwright reissued a “buy” rating and issued a $50.00 price objective on shares of Seaport Therapeutics in a report on Thursday, August 20th. Wall Street Zen upgraded shares of Seaport Therapeutics to a “hold” rating in a research report on Saturday, May 9th. Finally, Stifel Nicolaus initiated coverage on Seaport Therapeutics in a research note on Tuesday, May 26th. They issued a “buy” rating and a $30.00 target price for the company. Six analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $37.33.

Insider Buying and Selling

In other Seaport Therapeutics news, Director Robert J. Hombach acquired 13,000 shares of the firm’s stock in a transaction that occurred on Monday, June 22nd. The shares were purchased at an average cost of $18.14 per share, for a total transaction of $235,820.00. Following the completion of the acquisition, the director owned 13,000 shares of the company’s stock, valued at approximately $235,820. The trade was a ∞ increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Seaport Therapeutics Price Performance

Shares of SPTX traded down $1.12 during midday trading on Friday, hitting $25.13. The company’s stock had a trading volume of 69,922 shares, compared to its average volume of 208,965. The company has a market cap of $1.35 billion and a PE ratio of -2.07. The company’s fifty day moving average price is $21.69. Seaport Therapeutics, Inc. has a one year low of $14.85 and a one year high of $28.38.

Seaport Therapeutics (NASDAQ:SPTX) last issued its quarterly earnings data on Monday, August 3rd. The company reported ($1.78) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.71) by ($1.07). As a group, equities analysts forecast that Seaport Therapeutics, Inc. will post -4.6 EPS for the current year.

Seaport Therapeutics Profile

Seaport Therapeutics Inc is a clinical-stage therapeutics company focused on inventing and developing new medicines for patients with depression, anxiety and other debilitating neuropsychiatric disorders. Seaport Therapeutics Inc is based in BOSTON.